Population pharmacokinetics of recombinant human <scp>C1</scp> inhibitor in patients with hereditary angioedema

Abstract

The population PK model for C1INH supports a dosing scheme on a 50 U kg(-1) basis up to 84 kg, with a fixed dose of 4200 U above 84 kg. The PK of rhC1INH following repeat administration are consistent with the PK following the first administration.